Vol. 4 No. 4 (2024)
Reimbursement Reviews

Sacituzumab Govitecan (Trodelvy)

decorative image of the issue cover

Published April 24, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses sacituzumab govitecan (Trodelvy), 180 mg lyophilized powder for solution for injection, for IV use.
  • Indication: For the treatment of adult patients with unresectable, locally advanced or metastatic, HR-positive, human epidermal growth factor receptor 2-negative (immunohistochemistry [IHC] 0, IHC 1+ or IHC 2+/in situ hybridization-negative) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.